|1.||Karhunen, Pekka J: 1 article (07/2006)|
|2.||Kellokumpu-Lehtinen, Pirkko: 1 article (07/2006)|
|3.||Mikkelsson, Jussi: 1 article (07/2006)|
|4.||Kallio, Jukka P: 1 article (07/2006)|
|5.||Tammela, Teuvo L J: 1 article (07/2006)|
|6.||Lam, Nicole Y-L: 1 article (12/2002)|
|7.||Leung, Yonna: 1 article (12/2002)|
|8.||Rainer, Timothy H: 1 article (12/2002)|
|9.||Cocks, Robert A: 1 article (12/2002)|
|10.||Ng, Margaret H-L: 1 article (12/2002)|
|1.||Migraine Disorders (Migraine)
09/01/1987 - "Platelet fibrinogen receptors in migraine patients."
01/01/1996 - "Blood platelet fibrinogen receptors in migraine and related headaches."
04/12/1990 - "Expression of fibrinogen receptors in platelets of migraine patients--correlation with GPIIb content and plasma cholesterol--reply."
06/30/1989 - "Expression of fibrinogen receptors in platelets of migraine patients--correlation with platelet GPIIb content and plasma cholesterol."
06/30/1989 - "There was a high correlation between the number of fibrinogen receptors exposed by ADP and the total amount of platelet GPIIb both in migraine patients (R = 0.69, p less than 0.01) and controls (R = 0.62 p less than 0.01), as well as plasma cholesterol in the case of migraine patients (R = 0.82, p less than 0.001)."
|2.||Thrombasthenia (Glanzmann Thrombasthenia)
10/01/1990 - "The triggering of fibrinogen receptors on mononuclear phagocytes of healthy subjects and of a thrombasthenia Glanzmann patient promotes the generation of reactive oxygen species."
11/01/1990 - "Fibrinogen binding correlated closely with platelet glycoprotein IIb-IIIa expression in members of a family with Glanzmann's thrombasthenia, and, in double labelling experiments, with the binding of PAC1, a monoclonal antibody that binds to GP IIb-IIIa only after the exposure of fibrinogen receptors. "
10/16/1986 - "However, future prospects in the treatment of angina pectoris include: drugs modifying the arachidonic acid cascade by increasing synthesis or release of prostacyclin (nafazatrom) or decreasing prostacyclin degradation (almitrine), or blocking thromboxane A2 synthetase (dazoxiben) or thromboxane A2 receptors (BM 13177) or, blocking the lipoxygenase pathway (nafazatrom) or prostacyclin analogues (iloprost); more clot-specific thrombolytic agents and new oral anticoagulant drugs; free-radical scavengers such as superoxide dismutase, catalase or peroxidase and drugs inhibiting xanthine-oxidase; anti-platelet drugs such as ticlopidine which blocks the fibrinogen receptors of platelets; drugs preventing the progression of atherosclerosis lesions such as nifedipine or verapamil in animals fed high-lipid diets; drugs which could modify myocardial metabolism during ischaemia. "
|5.||Wounds and Injuries (Trauma)
|2.||Adenosine Diphosphate (ADP)
|3.||Platelet Membrane Glycoprotein IIb
|4.||Arachidonic Acid (Vitamin F)
|6.||Reactive Oxygen Species (Oxygen Radicals)
|8.||Free Radical Scavengers